InSite Vision
This article was originally published in The Gray Sheet
Executive Summary
ISV-900 glaucoma test for identification of multiple genetic mutations using a single DNA sample from a patient's mouth is slated to launch in the second half of this year, the company said during a Feb. 13 teleconference. Firm files Form S-3 with Securities and Exchange Commission but has no plans to carry out initial public offering, officials said